Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Total Debt (2016 - 2025)

Historic Total Debt for Guided Therapeutics (GTHP) over the last 14 years, with Q3 2025 value amounting to $108000.0.

  • Guided Therapeutics' Total Debt fell 9087.07% to $108000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $108000.0, marking a year-over-year decrease of 9087.07%. This contributed to the annual value of $165000.0 for FY2024, which is N/A changed from last year.
  • Latest data reveals that Guided Therapeutics reported Total Debt of $108000.0 as of Q3 2025, which was down 9087.07% from $95000.0 recorded in Q2 2025.
  • In the past 5 years, Guided Therapeutics' Total Debt ranged from a high of $1.2 million in Q2 2024 and a low of $95000.0 during Q2 2025
  • Its 4-year average for Total Debt is $539428.6, with a median of $598000.0 in 2021.
  • As far as peak fluctuations go, Guided Therapeutics' Total Debt surged by 5188.36% in 2021, and later tumbled by 9201.01% in 2025.
  • Over the past 4 years, Guided Therapeutics' Total Debt (Quarter) stood at $680000.0 in 2021, then plummeted by 85.29% to $100000.0 in 2022, then skyrocketed by 65.0% to $165000.0 in 2024, then plummeted by 34.55% to $108000.0 in 2025.
  • Its Total Debt was $108000.0 in Q3 2025, compared to $95000.0 in Q2 2025 and $107000.0 in Q1 2025.